DEG2MOL is proposed, a biologically grounded conditioning framework that encodes differentially expressed gene profiles through a Gene Ontology (GO)-informed encoder and maps this representation into the latent space of a frozen, pre-trained scaffold-aware VAE via conditional latent flow matching.
Abstract
Transcriptomic profiles capture cellular responses to perturbations, offering a principled foundation for biologically grounded de novo drug design. However, existing transcriptome-guided generative approaches remain limited in biological specificity, transcriptomic coverage, and evaluation across diverse perturbation contexts. Here, we propose DEG2MOL, a biologically grounded conditioning framework that encodes differentially expressed gene profiles through a Gene Ontology (GO)-informed encoder and maps this representation into the latent space of a frozen, pre-trained scaffold-aware VAE via conditional latent flow matching. When benchmarked against five baseline models, DEG2MOL ranked first by rank-sum aggregation of six metrics in both the random- and scaffold-split evaluations. For two representative compound conditions, GO-informed encoder activations were accompanied by enrichment of the corresponding target-engaging pharmacophores among the generated molecules. In docking case studies of two compound–target pairs, generated molecules showed favorable predicted docking scores and reference-associated contacts. DEG2MOL also generated molecules from shRNA knockdown, CRISPR knockout, and Perturb-seq profiles without additional training, indicating transfer across the perturbation types and profiling platforms evaluated. At the transcriptional level, an in silico gene-expression analysis showed that the predicted signatures of generated molecules were more similar to those of target-matched inhibitors than to those of unrelated inhibitors. The data and code are available at https://github.com/KU-MedAI/DEG2MOL.
AET5 is presented, a de novo molecular generation framework that conditions molecular design on disease-reversal gene expression profiles, providing a general framework for biologically informed drug design under noisy transcriptomic conditions.
Zhi-Kang Yuan, Xin Zhang, Gao-Ming Lin et al.· PLoS Computational Biology· 0 citations
MIRCID, a framework comparing gene expression with inferred transcription factor activity and miRNA expression across pathway classification and similarity-based MoA retrieval, supports inferred HubmiRs as a biologically informed recoding of transcriptomic data for perturbational drug modeling, while leaving recovery o...
An artificial intelligence framework that integrates biological mechanism knowledge to predict how cells respond to chemical perturbation, improving generalization to untested drugs and prioritizing cancer drug candidates in virtual screening is introduced.
Abstract Accurate prediction of anticancer drug response remains challenging because conventional approaches based on chemical structures and baseline molecular profiles do not directly capture drug-induced perturbations or cellular dependencies. Here, we present vulnerability-guided cascaded attention transformer (VCA...
Chong-Hao Chen, Yu-Le Du, Ya-Xin Jiang et al.· Briefings in Bioinformatics· 0 citations
A symmetric three-class predictor of DrugComb ZIP interactions was developed and compared all seven combinations of landmark expression, Hallmark pathway scores and CollecTRI regulon activities, demonstrating that the predictive value of functional context representations depends on both the type of domain shift and th...
Elizaveta Ignatova, M. Likhter· bioRxiv· 0 citations
Summary Gut microbial and endogenous metabolites are key regulators at the interface of host metabolism and immunity, yet their global effects on human T cell states remain poorly defined. Here, we profile primary human T cell responses to 364 endogenous and microbiota-derived metabolites using high-throughput digital...
Yi-Yang Xu, Yi-Heng Zhao, Si-Zhe Yang et al.· iScience· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.